Table 1.
Characteristics of included randomized controlled trials
| Study | Arm | Sample size | Study period/design | Country | Age | Gender male | Lesion size (cm) | Location head/uncinate | Stylet use | Suction | ROSE | Needle |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alatawi et al., 2015[18] | FNB FNA | 50 50 | 2012-2013/parallel | France | 67.8±13.1 68±11.2 | 28 (56%) 35 (70%) | 3.2±0.5 3.3±0.2 | 34 (68%) 38 (76%) | No | Yes | No | ProCore® Echo Ultra® |
| Bang et al., 2012[19] | FNB FNA | 28 28 | 2011/parallel | USA | 65±15.4 65.4±11.1 | 15 (53.6%) 16 (57.1%) | 3.2±0.9 3.3±0.7 | 20 (71.4%) 20 (71.4%) | No | Only in FNB group | Yes | ProCore® Expect® |
| Bang et al., 2018[20] | FNB FNA | 4646 | Cross-over | USA | 67.9±14.7 | 28 (60.9%) | 2.9±0.8 | 28 (60.9%) | NR | No | Yes | Acquire® Expect® |
| Cheng et al., 2018[21]* | FNB FNA | 123 126 | 2014-2016/parallel | China | 58.3±11.1 58.3±12.2 | 59.3% 63.6% | 2.91 2.95 | NR | Only at first two passes | Only at 3 and 4 passes | No | ProCore® EchoTip® |
| Ganc et al., 2014[22]a | FNB FNA | 30 30 | Cross-over | Brazil | NR | NR | NR | NR | NR | NR | No | ProCore® EchoTip® |
| Hucl et al., 2013[23]* | FNB FNA | 69 69 | 2011-2012/cross-over | India | 51.7±13.6 | 37 (53.6%) | 4.19±1.7 | 54% | No | Yes | No | ProCore® EchoTip® |
| Lee et al., 2017[24]* | FNB FNA | 9 7 | 2013-2014/parallel | Korea | 69 (26-85) 66 (36-81) | 62% 75.8% | 4.4±3.2 3.7±2 | NR | Yes | Partially | No | ProCore® EchoTip® |
| Noh et al., 2018[25] | FNB FNA | 60 60 | 2013-2015/cross-over | Korea | 61.6±10 | 35 (58.3%) | 3.1±0.8 | 23 (38.4%) | No | No Yes | No | ProCore® EZShot 2® |
| Othman et al., 2017[26] | FNB FNA | 29 60 | 2013-2014/parallel | USA | 67.9±10.3 63.4±10 | 16 (55.1%) 27 (45%) | NR | 16 (55.1%) 30 (50%) | No | Yes | Yes | ProCore® EZShot 2®/Expect® |
| Sterlacci et al., 2016[27]* | FNB FNA | 38 38 | 2011-2013/cross-over | Germany | 68±12 | 51.8% | 3.3±1.2 | NR | No | Yes | No | ProCore® EchoTip® |
| Vanbiervliet et al., 2014[28] | FNB FNA | 80 80 | 2012/cross-over | France | 67.1±11.1 | 49 (61.2%) | 3.3±1 | 50 (62.5%) | No | Yes | No | ProCore® EchoTip® |
*Trials including either pancreatic and extra-pancreatic masses. Only pancreatic lesions were reported in the table and included in the analysis, aConference abstract, bThree-arm trial comparing two different FNA needles and FNB. Data from the two FNA arms were merged. FNB: Fine-Needle Biopsy; ROSE: Rapid on-site evaluation; NR: Not reported